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ABSTRACT –  The Medical Imaging Laboratory is a research group within the Hospital
General Universitario Gregorio Marañón. The main research line of the group is focused
towards the development and exploitation of medical imaging techniques, including the
development of new processing tools for image analysis in clinical and preclinical rese-
arch. The group has a multi-disciplinary profile and a priority for translational research to-
pics, derived from real problems faced by the clinical specialists. One of the main research
areas is the development of technologies for molecular imaging, some of which have been
transferred to the industry and are now among the top products of the market. These sys-
tems include high-resolution PET, CT and PET-CT. Over the last years the group has de-
veloped several software tools to enable quantification of multimodal brain images using
morphometric and functional data. Some research applications of these hardware and soft-
ware tools are illustrated in the paper.
Received 8 January 2009
Revised 3 April 2009
Accepted 3 April 2009
1
Resources
The Medical Imaging Laboratory was creat-
ed in the early 90’ as a small group embedded
in the general research Department of the Hos-
pital General Universitario Gregorio Marañón
at Madrid. Parallel to the enormous expansion
in the field of medical imaging, during the past
decade the group underwent an exponential
growth in human resources (from less than 5 to
35) and technical means. The facilities of the
Neuroimaging Research Laboratory include a
space of 350 m2 that include offices, electron-
ic workshop, and animal imaging laboratory.
The most significant facilities are molecular
imaging scanners of several modalities, for
preclinical use (high resolution CT, PET, MRI,
SPECT, and Optical Imaging). Funding during
the last six years has come from more than 30
national or international research projects
granted to the group, from public or private
programs, as well as from technology transfers
to the industry.
Research
The main research line of the group is fo-
cused towards the development and exploita-
tion of medical imaging techniques, including
the development of new processing tools for
image analysis in clinical and preclinical re-
search. The group has a noticeable multi-disci-
plinary profile and its location within the Hos-
pital warrants an excellent connection with
clinicians and ensures a higher priority for
translational research topics, derived from real
problems faced by the clinical specialists. The
multi-disciplinary composition of the group
allows for a rapid validation of the results ob-
tained in the research projects, also facilitating
the technology transfer to industry. Some of
the main research topics of the group in the
field of neuroimaging are presented below.
High resolution imaging of
laboratory small animals
Molecular imaging techniques applied to
animal models are an excellent tool to study
pathological processes. One of the main re-
search areas in our group is the development of
technologies for molecular imaging, some of
which have been transferred to the industry
and are now among the top products of the
market. These systems include high-resolution
positron emission scanners (PET) computer-
ized tomography scanners (CT) and its combi-
nation (PET-CT) (Figure 1), nowadays one of
the most useful tools for biomedical research
in the area of molecular imaging1,2. PET en-
ables the monitoring of biochemical processes
“in vivo” at a molecular level. This technique
has multiple applications in the development
of new drugs, in the study of human diseases
on animal models or in the characterization of
the genomic expression and phenotypical
changes caused by genetic manipulation
(transgenic, knock-out or knock-in animals).
An ongoing imaging project deals with the
cerebral damage produced by the new “de-
sign” drugs (MDMA, methamphetamine).
The main objective of the study is to combine
PET and CT techniques to evaluate the dam-
age to serotonergic neurons and to determine
whether there is damage to dopaminergic neu-
rons, taking into account factors such as sex,
type of drug and dosage scheme. The two sub-
stances selected were MDMA and metham-
phetamine, the former with a clear preference
for the serotonergic system and perhaps for
the dopaminergic system; and the latter with a
preference for the dopaminergic system3.
With the help of high-resolution animal PET-
CT we can correlate serotoninergic and
dopaminergic changes with changes in brain
function and with its exact location in the
brain. Furthermore, the study aims to deter-
mine to what extent the neurons may recover
from the damage induced by MDMA. 
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Brain Imaging quantification
Over the last years the group has devel-
oped several software tools to enable quan-
tification of multimodal brain images using
morphometric and functional data. One of
these software tools is based on the Talairach
proportional grid system4,5. Using this tool
we can benefit from the anatomical informa-
tion of structural images to quantify func-
tional images that have poor spatial resolu-
tion, like such as PET or perfusion (cerebral
blood volume) scans (Figure 2).
The Talairach quantification tool is an ap-
plication of the Talairach proportional grid
system6, used as a method for semiautomat-
ic segmentation and analysis of MRI and
functional images (PET, or Cerebral Blood
Volume maps obtained by MR Perfusion
weighted images). The method can be de-
scribed as a multimodal application where
the anatomical information of the MRI is
used to build the Talairach grid and a co-reg-
istered functional image is superimposed on
the same grid. By doing so, the Talairach-
normalized tessellation of the brain is di-
rectly extended to functional images, allow-
Figure 1. An illustration of molecular imaging. Triplanar view of an 18F-FDG PET rat study fused with a CT of the same
animal. Images were acquired with the VrPET/CT, a system developed in our group.
Figure 2. A screenshot of the software tool developed for volumetric and functional quantification of brain images. The triplanar
view shows a Talairach grid built upon an MRI and a co-registered PET superimposed for quantification. For each of the 1,065
cells of the grid, volume and metabolic data is obtained for each brain tissue (total or WM, GM, CSF separately).
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ing for a convenient regional analysis of
volume and activity rates of brain struc-
tures, defined in the Talairach Atlas as sets
of cells. This procedure requires minimal
manipulation of brain geometry, thus fully
preserving individual brain morphology.
The brain standardization proposed in the
Talairach grid system begins with a reorien-
tation centered on the anterior and posterior
commissures and the inter-hemispheric
plane as the vertical axis, followed by a
piecewise linear transformation that pro-
duces a tessellation of the brain into a 3D
grid of 1,056 cells representing homologous
brain regions across subjects. This subdivi-
sion of the brain according to the Talairach
grid system allowed us to use it as the basis
for a segmentation method for inter-subject
comparisons, by defining brain regions of in-
terest (ROI) as sets of 3D volume grid cells
or ‘boxels’. Following this procedure for
defining ROI’s we have been identified over
20 brain regions, from which we can obtain
volume data for each tissue (Gray Matter,
White Matter, and CSF), metabolic activity
(PET) or perfusion (cerebral blood volume),
for the whole brain parenchyma or separate-
ly for each tissue. Using this tool, we obtain
data for more than 400 anatomical and func-
tional variables4,5. This software have been
used in numerous publications related to
structural and functional alterations of psy-
chiatric patients.
Effect of spatial normalization
on voxel-wise studies
In pathologic brains with morphological
alterations, the process of spatial normaliza-
tion, as performed by Statistical Parametric
Mapping (SPM) methods, may introduce a
confounding effect in the measurement of
functional (metabolic) activity data. We have
investigated the effect of the spatial normal-
ization of PET images, using MRI and PET
studies of schizophrenic patients and con-
trols7. Using the Talairach-based segmenta-
tion tool mentioned above, and manual seg-
mentation, we measured regional metabolic
activity in the untransformed brains and after
their spatial normalization. We observed that
the spatial normalization has little effect for
large ROIs, such as the main brain lobes, even
in brains showing pronounced morphological
abnormalities. However, smaller structures as
the caudate nucleus show a considerable
change in metabolic activity values after nor-
malization. This normalization bias is much
larger in patients than in controls, and may
lead to artifactual differences between both
groups if the data are assessed by means of
voxel-wise methods (SPM). We concluded
that spatial normalization of the PET images
of pathologic brains may introduce a poten-
tial source of error that should be taken into
account in the analysis of functional data, in
particular, when studying small brain nuclei
as the caudate7.
Neuroimaging studies in
neurogical and mental
diseases 
In the field of medical imaging, the neurog-
ical and mental diseases are one of the most
typical examples of problems which require a
multidisciplinary approach. Following a mul-
timodality strategy to describe structural and
functional brain alterations, in our research
group we make use of the following tech-
niques: structural imaging (MR, CT), for vol-
umetric and morphometric studies; magnetic
resonance spectroscopy (MRS), for measure-
ments of some neural metabolites (N-acetil-
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aspartate, creatine, choline, mio-inositol);
perfusion, to measure microvascularization of
cerebral tissue; diffusion tensor imaging, for
measurements of White Matter anisotropy
and tractography; and PET imaging using
18F-FDG as tracer, for measurement of glu-
cose metabolism as a marker of neuronal
activity.
Schizophrenia 
The interest of quantitative data extracted
from the neuroimaging studies in schizo-
phrenia derives from multiple previous find-
ings of groups of schizophrenic patients
who show functional and structural brain al-
terations (e.g., atrophy of frontal cortex),
sometimes related to clinical manifestations
(predominating symptoms, evolution, phar-
macological response) or to treatment. To
generate accurate quantitative data, we mea-
sure the volume of the main brain lobes and
their tissues (WM, GM and CSF), exploring
the structural alterations detectable in chron-
ic and recent onset patients. Among the key
findings in our studies, we have found signif-
icant clinical and biological differences be-
tween treatment resistant and non treatment
resistant schizophrenia patients8. These dif-
ferences included greater clinical severity in
the treatment resistant sample at baseline,
and different baseline anatomical (volumet-
ric) and electrophysiological (response to
P300) parameters, together with longitudinal
changes in cerebral volumes after treatment
with atypical neuroleptics. The structural dif-
ferences showed a significant degree of sen-
sitivity and specificity, which supports the
existence of a distinct subgroup of patients
with marked frontal deficits and a poorer re-
sponse to treatment within the spectrum of
schizophrenia8.
Alzheimer’s disease
An early diagnosis of AD and its discrim-
ination against other types of dementias
(Lewy, fronto-temporal) are key issues to
establish the appropriate treatment, the
prognosis and a forecast of the forthcoming
social needs of the patient. To achieve an
earlier and more reliable diagnosis, a com-
bined used of several imaging techniques
have been proposed, with the aim of detect-
ing early changes associated with the dis-
ease. In order to detect structural and func-
tional alterations, 18F-FDG PET images are
used in combination with four MRI tech-
niques: 1) Anatomical image sequences T1
and T2, for volumetric measurements; 2)
spectroscopic studies, to assess the bio-
chemical changes in neurological metabo-
lite markers such as N-acetyl-aspartate,
Choline, and Creatine; 3) perfusion studies,
to assess the functionality of parenchymal
microvasculature and 4) DTI studies, to
asses the integrity of white matter tracts.
Preliminary results show lower volumes of
GM and less blood volume flow in the tem-
poral lobe of patients with severe dementia
symptoms compared with patients with mild
dementia, suggesting that we can distinguish
between different degrees of cognitive im-
pairment at early stages of AD9.
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